NEUROMYELITIS OPTICA SPECTRUM (AQP-4/MOG) - (S)

Test Code: NMOS

Restricted to Neurologists or via prior approval.
Complete the pre-approval form by clicking on the following link:
http://clients.intelex.com/DSManitobav5/dcDocumentRetrieveExt.asp?sAuth=5e452e805fc5ade05fbae9ab88f227850bb762a71e3575a51efd1362c4724f16&fromDcPublic=1&DocumentID=9467

This test provides semiquantitative in vitro determination of human antibodies of immunoglobulin classes IgG against aquaporin-4 (AQP-4) and myelin-oligodendrocyte glycoprotein (MOG) in patient samples to support the diagnosis of demyelinating diseases of the central nervous system.  
Testing is performed at St. Boniface Hospital Immunology Lab using an indirect Immunofluorescence assay (IFA).  Serum samples are initially screened at a 1:10 dilution utilizing slides coated with transfected cells.  
A correlation between the titre and the clinical prognosis is not known.
Titers of antibodies against AQP-4 are significantly higher in serum than in CSF.  In contrast to anti-NMDA receptor encephalitis, in which intrathecal synthesis of autoantibodies occurs, the anti-AQP-4 antibodies in CSF originate from the peripheral lymphatic tissue.  They only enter the CSF when a critical serum-CSF gradient has been reached. Testing in CSF is not available.

_SH Immunology Autoimmune Laboratory Requisition (R250-10-85)

< 1:10 TITRE (Negative)
Positive results will be accomplished with a titre.

A diagnosis should not be made based on a single test result.   The clinical symptoms of the patient should always be taken into account along with the serological results by the physician.

Weekdays TAT 5-7 days/ Restricted to Neurologists or prior arrangement only